America’s biopharmaceutical companies turned a once in a generation challenge into reality by delivering safe and effective COVID-19 vaccines and treatments to patients in record time. COVID-19 vaccines have leaned on new platform technologies and scientific advancements, which have transformed how we fight infectious disease. Innovative treatment approaches have further reduced hospitalizing for severe infection. But our work isn’t done. As variants emerge, the biopharmaceutical industry is working to learn more, be prepared and develop additional solutions to protect us against COVID-19 and future pandemics.
The biopharmaceutical industry has provided financial support and in-kind donations to organizations, patients and first responders, and continues to collaborate with U.S. and global health authorities to combat this global public health emergency.